Alopecia universalis
Methodology & AI Transparency ⓘ
Alopecia universalis Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Designated in federal medical registries as L63.1, Alopecia universalis falls under Hair & Scalp management, where androgens) [Alopecia universalis L63.1] establishes baseline severity and rules out diagnostic mimics.
- 2 Real-world patient consensus: Diagnostic registry L63.1: Alopecia universalis is managed within Hair & Scalp.
- 3 Typical cash cost range: Primary evaluation for Alopecia universalis incorporates androgens) [Alopecia universalis L63.1] and symptom diary review.
- 4 Top reported side effects / signs: Key Hair & Scalp biomarkers for Alopecia universalis (L63.1): TSH & Free in Alopecia universalis (L63.1: T4) & 25-Hydroxy Vitamin D in Alopecia universalis (L63.1: & Zinc) (25(OH)D 45 – 70 ng/mL (L63.1)).
Ask our AI Specialists anything about Alopecia universalis
What Is Alopecia universalis?
Designated in federal medical registries as L63.1, Alopecia universalis falls under Hair & Scalp management, where androgens) [Alopecia universalis L63.1] establishes baseline severity and rules out diagnostic mimics.
Pathophysiology, Underlying Causes & Clinical Presentation
Biological expression of Alopecia universalis (L63.1, Hair & Scalp) reflects perifollicular autoimmune lymphocytic in Alopecia universalis (L63.1: attack (alopecia areata)). longitudinal control is benchmarked via TSH & Free in Alopecia universalis (L63.1: T4).
Common Symptoms & Clinical Signs
- • Presentation of Alopecia universalis (L63.1): excess telogen hair in Alopecia universalis (L63.1: shedding)
- • Secondary Alopecia universalis clinical sign: discrete smooth circular in Alopecia universalis (L63.1: patches of sudden)
- • Symptom flares in Alopecia universalis correlating with TSH & Free in Alopecia universalis (L63.1: T4) deviation outside TSH 0.8 – 2.5 mIU/L (L63.1)
- • Functional hair & scalp impact requiring androgens) [Alopecia universalis L63.1] evaluation (L63.1)
Alopecia universalis Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | L63.1 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Hair Loss, Alopecia & Scalp Conditions | NLM Clinical Tables |
| Diagnostic / Lab Marker: TSH & Free in Alopecia universalis (L63.1: T4) | TSH 0.8 – 2.5 mIU/L (L63.1) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: 25-Hydroxy Vitamin D in Alopecia universalis (L63.1: & Zinc) | 25(OH)D 45 – 70 ng/mL (L63.1) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Total/Free Testosterone & in Alopecia universalis (L63.1: DHEA-S (if androgenic)) | Age/sex physiological range (L63.1) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Alopecia universalis
Treatment selection for Alopecia universalis depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Alopecia universalis)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Efficacy comparison of monotherapies and combination therapies for androgenetic: What a 3,133-Participant Study Found In recent years, combination therapies are showing significant promise as potential therapies. Dermatologic therapy • 2022-03-15 • Meta-Analysis | N = 3,133 | 99/100 | PMID 34897933 ↗ |
| New Insights on Combination Therapy in Androgenetic hair loss: A Network Meta-Analysis of: What a 3,012-Participant Study Found Based on the current studies, we found that the combination of Minoxidil with spironolactone, PRPF, flutamide, and finasteride may offer better treatment outcomes for patients with androgenetic hair loss. Aesthetic plastic surgery • 2026-07-15 • Meta-Analysis | N = 3,012 | 99/100 | PMID 42168420 ↗ |
| New Insights on Skin-applied Efinaconazole 10% for Onychomycosis: Pooled Phase 3 Analysis in: What a 1,655-Participant Study Found Applied to the skin efinaconazole 10% showed favorable efficacy/safety in White, Asian, and Black participants with mild-to-moderate onychomycosis. Journal of drugs in dermatology : JDD • 2026-01-01 • Phase III Randomized Trial | N = 1,655 | 96/100 | PMID 41493257 ↗ |
| New Insights on Glycolipid and Hormonal Profiles in Young Men with Early-Onset Androgenetic hair: What a 1,009-Participant Study Found The acknowledgement of this syndrome would be of importance to prevent the long-term consequences on health in the affected men. Scientific reports • 2017-08-10 • Meta-Analysis | N = 1,009 | 94/100 | PMID 28798373 ↗ |
| New Insights on Bilateral Association Between eczema® and hair loss: What a 233,448-Participant Study Found Based on 7 studies, there was a significant association between AD and AA when AA was the exposure factor [odds ratio, OR, = 4.537 (95% CI: 2.409-8.544)]; based on 10 studies, there was also a significant association between... Dermatitis : contact, atopic, occupational, drug • 2024-01-15 • Meta-Analysis | N = 233,448 | 94/100 | PMID 37471232 ↗ |
Alopecia universalis Patient Community & “People Like Me” Threads
Filter Alopecia universalis community threads and patient logs by age, biological sex, dosage, and treatment duration.